Skip to content

Effects of levosimendan on diaphragm function in mechanically ventilated patients

Effects of levosimendan on diaphragm function in mechanically ventilated patients - Levosimendan in mechanically ventilated patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON37368
Enrollment
42
Registered
2012-05-29
Start date
2012-09-18
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diaphragm dysfunction respiratory muscle weakness

Interventions

Subjects are treated with either levosimendan (continuous levosimendan infusion of 0.2 µg/kg/min) or placebo for 6 hours. Before treatment and after treatment patients perform a 30 minute weaning tr

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • age >18 year • mechanical ventilation for at least 3 days • PaO2/FiO2 ratio >200 mmHg • Ventilatory settings: Positive End Expiratory Pressure

Exclusion criteria

Exclusion criteria: • pre-existent muscle disease (congenital or acquired) or diseases / disorders know to be associated with myopathy including auto-immune diseases. • pre-existent cardiac disease (based on history, electrocardiography and transthoracic echocardiography) • upper airway / esophageal pathology (i.e. recent surgery, esophageal varices, diaphragmatic hernia) • phrenic nerve lesions • pregnancy, breast feeding • severe renal failure (serum creatinine > 450 µmol/L) • severe hepatic failure • recent (within 5 days) nasal bleeding

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is the difference in neuro-mechanical efficiency of the diaphragm (i.e. the ratio of diaphragm electrical activity [Edi] and transdiaphragmatic pressure [Pdi]) before and after levosimendan administration during a CPAP trial.

Secondary

MeasureTime frame
• Neuro-ventilatory efficiency of the diaphragm (i.e. the ratio of diaphragm electrical activity [Edi] and tidal volume [Vt]). • Oxygen consumption (VO2). • Carbon dioxide production (VCO2). • Oxygen level in blood (PaO2). • Carbon dioxide level in blood (PaCO2). • Accessory muscle recruitment (also in response to various pressure support level) i. electrical activity of the sternocleidomastoid muscle ii. electrical activity of the scalene muscles iii. electrical activity of the intercostal muscles iv. electrical activity of the genioglossal muscles

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)